Text Size
312 studies found for:    Hemophilia: Clinical Trials

Modify this search | How to Use Search Results

Show Display Options
Download search resultsDownload the search results for:
Hemophilia: Clinical Trials (312 records)
Need help? See Downloading Content for Analysis
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Recruiting Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery
Condition: Hemophilia A
Intervention: Drug: Recombinant Protein-Free Factor VIII (rAHF-PFM)
2 Active, not recruiting A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150
Condition: Hemophilia A, Hemophilia B
Interventions: Drug: BAY86-6150;   Drug: eptacog alfa [activated]
3 Completed Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901
Condition: Hemophilia A
Intervention: Drug: Antihemophilic factor, recombinant, manufactured protein-free
4 Recruiting A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B
Condition: Hemophilia B
Intervention: Biological: rIX-FP
5 Completed Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B
Conditions: Congenital Bleeding Disorder;   Haemophilia B
Intervention: Drug: 40K PEG-rFIX
6 Recruiting A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A
Condition: Hemophilia A
Intervention: Biological: BAY94-9027
7 Recruiting Validation Study of a cOmputer Pharmacokinetic Tool to assIst in the Follow up Care of haeMophilia A Patients
Condition: Haemophilia A
Intervention: Drug: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
8 Completed Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: NNC 0129-0000-1003
9 Completed Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101
Condition: Hemophilia A
Intervention: Drug: Antihemophilic factor, recombinant, manufactured protein-free
10 Completed Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study
Conditions: Hemophilia A;   Hemophilia B
Intervention:
11 Unknown † Once-A-Day Prophylaxis for Youth and Young Adults With Severe Hemophilia A
Condition: Hemophilia A
Intervention: Drug: Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS
12 Completed Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B
Interventions: Drug: activated recombinant human factor VII;   Drug: activated recombinant human factor VII analogue
13 Recruiting A Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of PF-05280602, A Recombinant Factor VIIa Variant (813d), In Adult Subjects With Hemophilia A Or B
Condition: Hemophilia A
Intervention: Biological: PF-05280602
14 Recruiting A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: NNC 0129-0000-1003
15 Completed Safety and Efficacy of N8 in Haemophilia A Subjects
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Interventions: Drug: recombinant factor VIII (N8);   Procedure: Blood drawn for laboratory testing
16 Recruiting An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
Condition: Hemophilia A
Intervention: Biological: Recombinant Factor VIII (rFVIII)
17 Completed Trial of NovoSeven® in Haemophilia - Joint Bleeds
Conditions: Congenital Bleeding Disorder;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors
Interventions: Drug: activated recombinant human factor VII;   Drug: Feiba VH
18 Terminated Early Prophylaxis Immunologic Challenge (EPIC) Study
Condition: Hemophilia A
Intervention: Biological: Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)
19 Completed Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX
Conditions: Congenital Bleeding Disorder;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors
Interventions: Drug: activated recombinant human factor VII;   Drug: Feiba VH
20 Recruiting Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody Development
Condition: Hemophilia A
Intervention: Biological: Biostate
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years